Specifications
- Assay duration:Multiple steps
- Assay Type (ELISA with LOV):Competitive
- Conjugate ELISA:Biotin
- Format:Pre-coated
- Host:Rabbit
- Primary antibody reactivity:Multiple
- Target protein:LRT
- Size:1 kit
- Sample Type:Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- Cross Reactivity:No significant cross-reactivity or interference between Liraglutide (LRT) and analogues was observed
- Detection Method:Colorimetric
- Time to Results:2 h
- Shelf Life:12 Months
- Detection Range:12.35 - 1000 pg/ml
- Storage Temperature:4 °C for one month (frequent use), −20 °C for one year
- Sample Volume:50 µl
- Sensitivity:4.64 pg/ml
- Regulatory Status:RUO
- Cat. No.:MSPP-CEV769GE
- No. of tests:96 wells
Specifications
About this item
This assay has high sensitivity and excellent specificity for detecting General species LRT (Liraglutide). The assay range is from 12.35 to 1000 pg/ml (Competitive kit) with a sensitivity of 4.64 pg/ml. There is no detectable cross-reactivity with other relevant proteins. Activity loss rate and accelerated stability test ect have been conducted to guarantee the best performance of the products after long storage and delivery.
- High sensitivity and specificity
- Perfect reproducibility and consistency across batches
- Quality control with three-level inspections
- Wide range of targets/species available
- Intra-assay: CV<10%; Inter-assay: CV<12%
Liraglutide is an acylated human glucagon-like peptide-1 (GLP-1) agonist, with a 97% amino acid sequence identity to endogenous human GLP-1(7-37). GLP-1(7-37) represents less than 20% of total circulating endogenous GLP-1. Like GLP-1(7-37), liraglutide activates the GLP-1 receptor, a membrane-bound cell-surface receptor coupled to adenylyl cyclase by the stimulatory G-protein, Gs, in pancreatic beta cells. Liraglutide increases intracellular cyclic AMP (cAMP), leading to insulin release in the presence of elevated glucose concentrations. This insulin secretion subsides as blood glucose concentrations decrease and approach euglycemia. Liraglutide also decreases glucagon secretion in a glucose-dependent manner. GLP-1(7-37) has a half-life of 1.5 to 2 minutes due to degradation by the ubiquitous endogenous enzymes, dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidases (NEP).